Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer
Clinical trial NCT07407452 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07407452
- Sponsor
- Jiangsu Cancer Institute & Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-01
- Primary completion
- 2027-12-31
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.